Association of Plasma Metabolomic Biomarkers with Chronic Ischemic White Matter Injury

NCT06608251 | Active Not Recruiting

• 1 other identifier: KY20240123-07
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The cases were screened according to the inclusion criteria, and after the patients signed the informed consent, the clinical data were collected, the imaging data were evaluated, and blood samples were taken for follow-up measurements. In the early morning of the second day after the patient was enrolled, 5mL of peripheral venous blood was drawn and sent to the neurology laboratory of our hospital for separation, and the detection of plasma metabolomics markers was performed.

Conditions

Myelinopathy

Outcome Measures

Primary Outcomes (1)

• myelinopathy

  The degree of damage to the white matter of the brain is judged based on the magnetic resonance Fazekas score(1-3), with the higher scores indicating the damage more severe.

  2024.06.01-2027.06.01

Interventions

white matter lesion DIAGNOSTIC_TEST

According to the results of magnetic resonance, they were divided into white matter degeneration group and non-white matter degeneration group

Eligibility Criteria

• Age: 45 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

older than 45 years old and without stoke be able to cooperate with the improvement of brain MRI examination

You may qualify if:

• Be older than 45 years old;
• Patients admitted to the Department of Neurology due to headache, vertigo, anxiety, etc.;
• There were no symptoms of neurological deficit on physical examination;
• Able to cooperate with the improvement of brain MRI examination;
• Sign the informed consent form.

You may not qualify if:

• History of stroke, traumatic brain injury, intracranial tumor, central nervous system infection, active malignant tumor, thyroid disease, autoimmune disease, active or chronic inflammatory disease, severe liver and kidney impairment, etc.;
• accompanied by neurological deficit symptoms;
• refusal to participate in the study;
• Other conditions judged by the investigator to be unsuitable for enrollment.

Sponsors & Collaborators

• Nanjing First Hospital, Nanjing Medical University: lead

Study Sites (1)

Nanjing First Hospital

Nanjing, Jiangsu, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

serum

Study Officials

• Ying Zhang, Doctor

  Nanjing First Hospital, Nanjing Medical University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 7, 2024
• First Posted: September 23, 2024
• Study Start: June 1, 2024
• Primary Completion: May 31, 2025
• Study Completion: May 31, 2025
• Last Updated: September 23, 2024

Record last verified: 2024-06

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)